Palliative and end-of-life care in advanced Parkinson's disease and multiple sclerosis

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 10, Issue 3, 2010, Pages 290-292

  Campbell, Colin W ^a   Jones, Edward J S ^b   Merrills, Jane ^c  

^a St Catherine's Hospice   (United Kingdom)

^b SCARBOROUGH HOSPITAL   (Canada)

^c HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Best interests; Multiple sclerosis; Palliative; Parkinson's disease; Terminal

Indexed keywords

MIDAZOLAM; ROTIGOTINE;

BULBAR PARALYSIS; DECUBITUS; DEMENTIA; DEPRESSION; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MEMORY DISORDER; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; PALLIATIVE THERAPY; PARKINSON DISEASE; PROGNOSIS; REVIEW; SPASTICITY; TERMINAL CARE;

EID: 77952999570     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.10-3-290     Document Type: Review

References (19)

1. Higginson IJ, Hart S, Silber E, Burman R, Edmonds P. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care 2006;22:158-165 (Pubitemid 44526011)
2. Lee MA,Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson's disease. J Pain Sympton Manage 2006;32:462-469 (Pubitemid 44666294)
3. National Institute for Health and Clinical Excellence. Management of multiple sclerosis in primary and secondary care, CG8. London: NICE, 2003.
4. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care, CG35. London: NICE, 2006.
5. Royal College of Physicians, National Council for Palliative Care and British Society of Rehabilitation Medicine. Longterm neurological conditions: management at the interface between neurology, rehabilitation and palliative care. London: RCP, 2008.
6. Department of Health. The National Service Framework for long term conditions. London: DH, 2005.
7. Snell K, Pennington S, Lee M,Walker R. The place of death in Parkinson's disease. Age Ageing 2009;38:617-619
8. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003;16:283-288 (Pubitemid 36688294)
9. Dubois B, Burn D, Goetz C et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Move Disord 2007;22:2314-2324 (Pubitemid 351155975)
10. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518 (Pubitemid 39603164)
11. Menza M, Dobkin RD,Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892
12. Goy ER, Carter JH, Ganzini L. Parkinson disease at the end of life: caregiver perspectives. Neurology 2007;69:611-612 (Pubitemid 47357271)
13. Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005;11:322-327 (Pubitemid 40775190)
14. www.adrtnhs.co.uk/index.html
15. Campbell C, Partridge R. Artificial nutrition and hydration. Guidance in end of life care for adults. London: National Council for Palliative Care, 2007.
16. Chapman S. The Mental Capacity Act in practice: guidance for end of life care. London: National Council for Palliative Care, 2008.
17. British Medical Association.Withholding and withdrawing life-prolonging medical treatment: guidance for decision making, 2nd edn. Oxford: Blackwell, 2003.
18. Thomas S, MacMahon D. Parkinson's disease, palliative care and older people: Part 1. Nurs Older People 2004;16:22-26
19. British National Formulary. Prescribing in palliative care. London: BNF, 2009.